The DOI matches its Crossref record.
Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus
Abstract
Ceftaroline (PPI 0903, formerly TAK-599), the active metabolite of a N-phosphono prodrug, ceftaroline fosamil, has been approved by the US Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. This antimicrobial agent binds to penicillin binding proteins (PBP) inhibiting cell wall synthesis and has a high affinity for PBP2a, which is associated with methicillin resistance. Ceftaroline is consistently active against multidrug-resistant Streptococcus pneumoniae and Staphylococcus aureus, including methicillin-resistant, vancomycin-intermediate, linezolid-resistant, and daptomycin-nonsusceptible strains. It possesses variable activity against Enterobacteriaceae and good activity against oral anaerobes. The drug is usually administrated intravenously at 600 mg every 12 h. Ceftaroline has low protein binding and is excreted by the kidneys and thus requires dose adjustments in individuals with renal failure. Clinical trials have demonstrated noninferiority when compared with vancomycin in the treatment of acute bacterial skin and skin structure infections and noninferiority when compared with ceftriaxone in the treatment of community-acquired bacterial pneumonia. Ceftaroline demonstrated a safety profile similar to that of comparator drugs in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects
Foster, T. J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux007 · Cited by 845
Mechanisms of Methicillin Resistance in Staphylococcus aureus
Peacock, S. J., & Paterson, G. K. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034516 · Cited by 656
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Combating Multidrug‐Resistant Bacteria: Current Strategies for the Discovery of Novel Antibacterials
O'Connell, K. M. G., Hodgkinson, J. T., Sore, H. F., Welch, M., Salmond, G. P. C., & Spring, D. R. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209979 · Cited by 435
Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them
Khameneh, B., Diab, R., Ghazvini, K., & Fazly Bazzaz, B. S. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.02.009 · Cited by 345
Metadata
- Authors
- Saravolatz, L. D., Stein, G. E., & Johnson, L. B.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-04
- Volume
- 52
- Issue
- 9
- Pages
- 1156-1163
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2167218440
- Cited by
- 173
- References
- 0
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus. https://app.cochat.ai/papers/10.1093/cid/cir147
- The paper
- Saravolatz, L. D., Stein, G. E., & Johnson, L. B. (2011). Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cir147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.